Xie et al.44 also highlighted the prevalence of chemoresistance in BCa, demonstrating that targeting NAT10 significantly enhances chemosensitivity in CSCs, characterized by high tumorigenicity, multipotent differentiation, and resistance to radiotherapy and chemotherapy45, mediating tumor initiation, maintenance, and potential distant metastasis, leading to poor prognosis46. The gene discussed is NAT10; the disease is neoplasm.